The FDA has approved Akeso Inc.’s penpulimab-kcqx in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic NPC.

CPTx GmbH, a pioneer in the therapeutic development and manufacturing of novel medicines built with single-stranded DNA, has ...